ArticleInvestigative ophthalmology & visual science2026
Structure-Based Network Analysis of AlphaFold Structure Predictions Identifies Putative Causative Variants of Inherited Retinal Disease.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: As sequencing improves, identifying variants causing inherited retinal diseases (IRDs) is essential for gene therapy. Structure-based network analysis (SBNA) predicts missense variant impact based entirely on structural first principles rather than historical phenotypic or clinical outcome data, distinguishing it among contemporary missense prediction tools. Here, we expanded the application of SBNA to artificial intelligence (AI)-generated protein structures, facilitating application to all known IRD-associated proteins. Methods: We first calculated SBNA scores for structures from the Protein Data Bank (PDB) and AI-generated structures from AlphaFold2, comparing scores for pathogenic and benign ClinVar variants. We then used these results to identify the putative genetic basis of disease for patients with IRDs, demonstrating the clinical applicability of this approach. Results: We found a significant difference between SBNA scores for known benign and pathogenic variants across all human protein structures from the PDB (median, -0.6 vs. 1.8; P < 0.0001; AUC = 0.763) and across the corresponding AlphaFold2 structures (median, -0.2 vs. 1.9; P < 0.0001; AUC = 0.755). This difference was also significant for AlphaFold2 structures from 374 IRD-associated proteins (median, -0.4 vs. 1.9; P < 0.0001; AUC = 0.779), including 185 without available structural data. This model identified likely causative disease variants in 56% of IRD patients without a known genetic basis for disease. Conclusions: SBNA can identify variants in human proteins that are likely to cause disease, and it can help predict variants causative of IRDs in an unbiased fashion using both AlphaFold2-generated structural models and experimental structural data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.